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Purpose: This study was designed to investigate the therapeutic effects of oral kallidinogenase 
medication as an adjuvant therapy in treating patients with diabetic macular edema (DME).
Study design: This was a prospective, open-labeled, randomized study.
Methods: All patients were given posterior sub-Tenon triamcinolone acetonide (STTA) 
injection and focal laser treatment session for DME. The patients were subdivided into two 
groups: 1) those treated with oral kallidinogenase for at least 6 months after local treatment 
(treated group) and 2) those treated without oral kallidinogenase (untreated group). In this 
study, best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal 
thickness (SCT), and chorioretinal blood flow level were measured in 17 patients (19 eyes). 
Chorioretinal blood flow levels at the disc and macula were measured by laser speckle flowg-
raphy and evaluated using the mean blur rate (MBR). These data were measured at baseline 
and at 1, 3, and 6 months after treatment initiation.
Results: BCVA at 6 months after treatment significantly improved in treated group (P,0.05). 
But the mean CRT after treatment significantly decreased in both groups. There was no significant 
difference in the mean SCT at baseline between the two groups. The mean SCT after treatment 
in treated group was significantly thinner than that before treatment (P,0.05). Compared to 
baseline (100%), MBR at the disc and the macula at 6 months after treatment significantly 
decreased to 84.8% and 86.2%, respectively, in untreated group (P,0.05), though it remained 
unchanged at 98.7% and 99.7% in treated group.
Conclusion: Oral kallidinogenase medication is useful as an adjuvant therapy to enhance the 
therapeutic effect of STTA in DME patients.
Keywords: kallidinogenase, diabetic macular edema, laser speckle flowgraphy, enhanced depth 
imaging optical coherence tomography
Introduction
Diabetic macular edema (DME) is the leading cause of blindness in patients with 
diabetic retinopathy worldwide.1 The pathogenesis of DME has long been attributed 
to retinal vascular hyperpermeability, which is associated with focal leakage from 
microaneurysms or diffuse leakage from incompetent capillaries when visualized on 
fluorescein angiography (FA). Functional imaging studies also showed a reduction in 
choroidal blood flow in the eyes of patients with diabetic retinopathy.2 However, the 
role of choroidal perfusion in the pathophysiology of DME remains unclear.3 Early 
Treatment Diabetic Retinopathy Study applied focal laser photocoagulation to leak-
age from microaneurysms and grid laser photocoagulation to leakage from capillary 
areas.4 In addition, many reports have been made on the effectiveness of sub-Tenon 
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triamcinolone acetonide (STTA) injection for the treatment 
of diffuse macular edema that is refractory to laser therapy.5,6 
This study was proposed due to the possibility of treatment 
that further enhances these effects. Kallidinogenase acts 
on kininogen in plasma to liberate kinins, thereby exert-
ing a peripheral vasodilating effect via the enhancement of 
nitrous oxide production. This process is believed to result in 
improved chorioretinal circulation and, in fact, certain reports 
have indicated that administration of this enzyme produces 
an increase in chorioretinal blood flow7–9 or results in an anti-
vascular endothelial growth factor (VEGF) effect.10,11 Kalli-
dinogenase is currently used in the treatment of patients with 
diabetic retinopathy or retinal vein occlusion in Japan. Recent 
studies of choroidal thickness in the eyes of patients with 
DME and proliferative diabetic retinopathy have produced 
diverging results, however, with some reports suggesting 
choroidal thickening, thinning, and no change in eyes with 
DME.12–15 Laser speckle flowgraphy (LSFG) allows for the 
quantitative estimation of blood flow changes in the optic 
nerve head, choroid, retina, and iris in vivo to make the same 
area measurable repeatedly in the same eye. It was developed 
to facilitate the noncontact analysis of ocular blood flow in 
living eyes, utilizing the laser speckle phenomenon.16–18 Our 
aims in this study were to investigate the therapeutic effects 
of oral kallidinogenase medication as an adjuvant therapy 
in treating patients with DME and to evaluate chorioretinal 
blood flow changes and choroidal thickness changes using 
LSFG and enhanced depth imaging optical coherence tomog-
raphy (EDI-OCT) as a result of this treatment.
Materials and methods
experimental design
This was a prospective, single center, open-labeled, random-
ized clinical study carried out at the Department of Ophthal-
mology, Nagasaki University, Japan.
Patients
Patients with type 2 diabetes who had DME were eligible for 
this clinical trial. The criterion for thickening of the central 
macula was defined as a central retinal thickness (CRT) of 
300 µm in the central subfield. This study was conducted in 
19 eyes of 17 consecutive patients. Snellen best-corrected 
baseline visual acuity (BCVA) was measured by a certified 
examiner for all patients. For baseline evaluation, all patients 
underwent slit-lamp examination, gonioscopy, intraocular 
pressure measurement with Goldmann tonometry, dilated 
fundus examination, FA, fundus photography, spectral domain 
optical coherence tomography (SD-OCT), LSFG, and blood 
pressure measurement before laser treatment. BCVA was 
expressed as the logarithm of the minimum angle of resolution 
(logMAR). BCVA was recorded at the baseline examination 
and at every subsequent visit. The exclusion criteria were 
corneal opacity, cataract, and vitreous hemorrhage that could 
influence vision and digital photography, history of ocular 
hypertension or glaucoma of the study eye, any previous ocular 
condition that may be associated with a risk of macular edema 
due to age-related macular degeneration and choroidal neo-
vascularization, planned intraocular surgery within 6 months, 
vitreomacular traction or epiretinal membrane on OCT scan, 
history of chronic renal failure or renal transplant for diabetic 
nephropathy, uncontrolled hypertension (180/100 mmHg), 
and any systemic medication that is known to be toxic to the 
retina or associated with a risk of macular edema. This study 
adhered to the principles of the Declaration of Helsinki and 
obtained approval from the Institutional Review Board (IRB) 
of the Nagasaki University to conduct this study. This study 
was registered with the University Hospital Medical Infor-
mation Network – Clinical Trials Registry (UMIN-CTR) of 
Japan (ID UMIN000005339; date of access and registration, 
April 1, 2011). All participants provided written informed 
consent and the nature and possible consequences of the study 
were explained to them. All participants were given STTA and 
focal laser treatment session for DME and were subdivided 
into two groups using the assignment table for randomization. 
First group patients were treated with oral kallidinogenase 
for at least 6 months after local treatment (treated group), 
whereas the second group patients were treated without oral 
kallidinogenase (untreated group).
Local treatment of DME
sTTa method
Under local anesthesia with oxybuprocaine hydrochloride 
eye drops, a conjunctival incision was made at the infer-
otemporal quadrant. Tenon’s incision was made midway 
between the inferior and lateral rectus muscles, about 7 mm 
posterior to the limbus, and the surface of the sclera was 
confirmed. A 25-gauge straight blunt cannula was inserted 
through the sub-Tenon space reaching the posterior pole and 
20 mg (0.5 mL) of triamcinolone acetonide (Kenacort-A®; 
40 mg/mL) was injected.
Focal laser method
The focal photocoagulation was performed using the follow-
ing parameters: wavelength 532 nm, spot size 50–60 µm, 
laser power 70–100 mW, and pulse duration 100 ms. The 
target was microaneurysms that were detected by FA.
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Effects of oral kallidinogenase on diabetic macular edema
Kallidinogenase medication
Oral kallidinogenase (CARNACULIN® Tablet 50 units; 
Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan) was 
administered to the treated group – a total of 150 units divided 
into 3 doses per day for 6 months.
Measuring chorioretinal blood flow
The principles of the LSFG technique, which are based 
upon and its applications in measuring blood flow of the 
optic disc, have been described in detail in the previous 
publications.16–18 The most recently available LSFG NAVI 
system (Softcare Co., Ltd., Fukutsu, Japan) uses a fundus 
camera that is equipped with a diode laser (wavelength, 
830 nm) and a highly sensitive charge-coupled device camera 
(750×360 pixels). Images are acquired continuously at the rate 
of 30 frames per second and then averaged to produce a com-
posite map of ocular blood flow. The primary measurement 
parameter of LSFG is mean blur rate (MBR), a measurement 
of the relative velocity of blood flow. The MBR displayed 
as a 2D color-coded map. Similarly, the LSFG provided the 
novel measurement parameter of the retinal vessel within or 
nearby the optic disc region. We determined the margin of 
the optic disc with a round rubber band. After circling the 
area around the optic disc, we then investigated the MBR of 
the major vessel (artery and vein) within this circle. Since 
the MBR in the vessel area (MV) includes the MBR in the 
tissue area (MT), the MBR used to evaluate the blood flow 
in the retinal vessel excluded the MT as choroidal blood flow 
(MV-MT) (Figure 1A). Also, we measured the choroidal 
blood flow at the macula by the following steps: First, we 
measured the MBR in the chorioretinal tissue at macular 
area, compared LSFG MBR maps with fundus photographs, 
configured isometric areas for analysis at macula, and then 
calculated the average blur rate in the whole area without 
separating vessels and tissues (Figure 1B). The parameters 
of MBR used in this study were calculated by the equipped 
software (LSFG Analyzer, version 3.0.39.0; Softcare Ltd.). 
We then saved the position of each region of interest in soft-
ware, and reused it in subsequent analyses of the same patient. 
We recorded the MBR of the optic disc and the chorioretinal 
blood flow at the macula before and after 1, 3, and 6 months 
of local treatment in both groups and calculated the percent-
age according to the pretreatment value (100%).
OCT measurements
CRT was measured by CIRRUS™ HD-CT (Carl Zeiss Med-
itec Inc., Dublin, CA, USA) using the macular cube 512×128 
protocol. The subfoveal choroidal thickness (SCT) was mea-
sured by SPECTRALIS™ SD-OCT (Heidelberg Engineering 
GmbH, Heidelberg, Germany) according to the EDI-OCT 
technique described by Spaide et al.19 The choroidal thickness 
was measured vertically from the outer border of the hyper-
reflective line corresponding to the retinal pigment epithelium 
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Figure 1 The mean blur rate (MBR) displayed as a 2D color-coded map. (A) MBR at the disc as the retinal blood flow, which was calculated automatically after circling the 
margin of the optic disc with a rubber band (). Since the MBR in the vessel area (MV) includes the MBR in the tissue area (MT), the MBR (MV-MT) was used as the retinal 
blood flow. (B) MBR at the macula which calculated automatically after configured isometric areas compared MBR maps with fundus photographs was used as the choroidal 
blood flow.
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measurements were made under the fovea. Both CRT and 
SCT were measured before and after 1, 3, and 6 months of 
local treatment of DME in both groups.
statistical analysis
Statistical analyses with the significance of BCVA, CRT, 
SCT, and MBR alterations were performed by repeated 
measures ANOVA followed by multiple comparisons Bon-
ferroni tests. Group comparisons were made using unpaired 
t-test, 2×2 chi-square tests, and Fisher’s test. P,0.05 was 
considered to be statistically significant.
Results
Patient demographics
The demographics of diabetic patients are shown in Table 1. 
Ten eyes were assigned to kallidinogenase-treated group and 
9 eyes were assigned to untreated group. There were 6 eyes 
with intraocular lens (IOL) in the treated group. On the other 
hand, there were 2 eyes with IOL in the untreated group. There 
was no statistically significant difference at baseline. Table 2 
also shows the mean BCVA, CRT, SCT, and MBR of both 
groups before and after 1, 3, and 6 months of local treatment. 
There was no statistically significant difference between the 
treated and untreated groups as regards BCVA, CRT, SCT, 
and MBR along the whole follow-up period except the MBR 
at the macula after 6 months of local treatment (P,0.05).
LogMAR BCVA
The logMAR of BCVA was 0.15 at baseline in the untreated 
group and changed to 0.18, 0.18, and 0.20 after 1, 3, and 
6 months of local treatment, respectively. However, the 
logMAR of BCVA was 0.20 at baseline in the treated 
group and changed to 0.18, 0.13, and 0.13 after 1, 3, and 
6 months of local treatment, respectively. BCVA signifi-
cantly improved in the treated group at 3 and 6 months from 
baseline (P,0.05) and remained unchanged in the untreated 
group (Figure 2A).
CrT measurements
Initially, the CRT was 369.6 µm at the baseline in the untreated 
group and reduced to 327.4, 311.2, and 310.7 µm after 1, 3, 
and 6 months of local treatment, respectively. Similarly, the 
CRT was 395.2 µm at the baseline in the treated group and 
reduced to 329.9, 327.1, and 341.2 µm after 1, 3, and 6 months 
of local treatment, respectively. There was a statistically sig-
nificant reduction as regards CRT during the whole follow-up 
period in both groups (P,0.05) (Figure 2B).
sCT measurements
Initially, SCT was 292.1 µm at the baseline in the untreated 
group and reduced to 281.7, 288.4, and 293.9 µm after 1, 3, 
and 6 months of local treatment, respectively. There was sta-
tistically significant reduction as regards SCT after 1 month of 
follow-up in untreated group (P,0.05) (Figure 2C). Similarly, 
SCT was 298.1 µm at the baseline in the treated group and 
reduced to 269.8, 283.7, and 287.1 µm after 1, 3, and 6 months 
of local treatment, respectively. There was statistically sig-
nificant reduction as regards SCT along the whole follow-up 
period in the treated group (P,0.05) (Figure 2C).
Change in retinal blood flow (MBR at the 
disc) and choroidal blood flow (MBR at 
the macula)
Retinal blood flow decreased in the untreated group with 
statistically significant reduction after 3 and 6 months of 
follow-up of local treatment (P,0.05) (Figure 3A). In contrast, 
the retinal blood flow remained unchanged in the treated group 
with no significant change along the whole follow-up period 
(Figure 3A). Although the choroidal blood flow decreased 
in the untreated group with statistically significant reduction 
after 6 months of follow-up of local treatment (P,0.05), it 
remained unchanged in the treated group with no significant 
change along the follow-up period (Figure 3B) after 6 months 
of local treatment a significant difference of (P,0.05) was 
found  between the two groups with regard to choroidal blood 
flow. Furthermore, there was a significant negative correlation 
between BCVA and retinal blood flow (MBR at the disc) in 
the treated group at 6 months (Figure 4).
Discussion
In this prospective study, oral kallidinogenase medication 
as an adjuvant therapy had a significant effect on functional 
Table 1 Demographics of patients with diabetic macular edema
Kallidinogenase (+) Kallidinogenase (−) P-value
Number of eyes 10 9 –
Mean age±SD (years) 62.1±4.91 62.4±0.46 0.46
Sex (male/female) 7/3 5/4 0.23
Lens (cataract/IOL) 4/6 7/2 0.17
Abbreviation: iOl, intraocular lens.
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Effects of oral kallidinogenase on diabetic macular edema
resolution after treatment for DME. Among the risk factors 
for diabetic retinopathy, VEGF is the predominant cytokine 
that accelerates vascular permeability and endothelial cell 
growth.20 The VEGF levels in the vitreous and aqueous 
humors of patients with diabetic retinopathy or DME were 
higher than that in patients without diabetic retinopathy or 
DME.21–23 Funatsu et al also reported that the VEGF level 
was related to the retinal thickness at the central fovea.21 
These results indicate that improved vascular permeability 
and decreased concentrations of VEGF in diabetes are crucial 
to stop the development of retinopathy and DME.
Recently, it has been reported that kallidinogenase nor-
malizes retinal vasopermeability8 and inhibits retinal and 
choroidal neovascularizations via the cleavage of VEGF165 
or VEGF 164.9–11 Furthermore, it was reported that tissue 
kallikrein administered intravenously normalizes retinal 
vasopermeability via suppression of the intraocular VEGF 
level in streptozotocin-induced diabetic rats.8 Kallidinoge-
nase, also known as kallikrein, is derived from blood plasma 
or tissue and has a serine protease that is capable of cleav-
ing kininogen to release vasoactive kinins.24 These kinins 
activate bradykinin B2 receptors and cause a peripheral 
vasodilating effect via the enhancement of nitrous oxide 
production. This process is believed to result in improved 
chorioretinal circulation.7 From these evidence, it can be 
concluded that the suppressive effect of kallidinogenase on 
Table 2 Changes in visual parameters over time
Baseline 1 month 3 months 6 months
Kallidinogenase + − + − + − + −
BCVA±SD (logMAR) 0.20±0.11 0.15±0.11 0.18±0.11 0.17±0.15 0.13±0.13 0.18±0.14 0.13±0.13 0.20±0.15
CrT±sD (µm) 395.2±89.8 369.6±67.4 329.9±72.0 327.4±34.9 327.1±76.2 311.2±39.0 341.2±126.9 310.7±44.7




















Notes: *Unpaired t-test; P,0.05.
Abbreviations: BCVA, best-corrected visual acuity; CRT, central retinal thickness; SCT, subfoveal choroidal thickness; MBR, mean blur rate; logMAR, logarithm of the 





















































































3 M 6 M
Kallidinogenase– Kallidinogenase+
Figure 2 (A) Change in the best-corrected visual acuity (BCVA). BCVA was significantly improved in the treated group at 3 and 6 months from baseline (*P,0.05) and 
remained unchanged in the untreated group. (B) Change in the central retinal thickness (CRT). CRT was significantly improved during the whole follow-up period in both 
groups (*P,0.05). There was no significant difference between the two groups. (C) Change in the subfoveal choroidal thickness (SCT). SCT was significantly reduced 
during the whole follow-up period in the treated group (*P,0.05). On the other hand, SCT was significantly reduced only at 1 month from baseline in the untreated group 
(*P,0.05).
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increased retinal vascular permeability can be attributed to 
a vascular protective effect resulting from the activation of 
the bradykinin–nitrous oxide system in addition to a VEGF-
suppressing effect.
In our study, we confirmed that BCVA was significantly 
improved in the treated group and remained unchanged 
in the untreated group, whereas CRT was significantly 
improved in both groups. This means that oral kallidinoge-
nase medication had not only morphological improvement 
but also functional improvement as an adjuvant therapy 
for DME. Since EDI-OCT allows the clinical evaluation 
of choroidal changes noninvasively,19 studies addressing 
choroidal thickness have been conducted for various retinal 
diseases.25–27 Choroidal ischemia may also play a role in the 
VEGF-driven response resulting in DME.25 Therefore, by 
blocking the action of VEGF on the choroid with kallidino-
genase therapy, the permeability of the choroidal vasculature 
decreases, which can be noted by a decrease in choroidal 
thickness. Sonoda et al reported that SCT of DME eyes 
was significantly reduced from the baseline by intravitreal 
triamcinolone acetonide or bevacizumab and suggested that 
the choroidal pathology in diabetic retinopathy might be 
due to steroid-sensitive factors rather than VEGF.28 In this 
study, we confirmed significant reduction in SCT in the 
treated group throughout the follow-up period and only in 
the first month in the untreated group. Although the decrease 
in choroidal thickness is not associated with visual or ana-
tomic outcomes, this sustainable reduction especially in the 
treated group suggests that oral kallidinogenase medication 
can extend the effects of STTA. The choroid contributes to 
the metabolic support of RPE and compromised choroidal 
blood flow can result in photoreceptor dysfunction and death 
with visual disability. Nagaoka et al reported that choroidal 
blood flow in patients with type 2 diabetes significantly 
decreased, especially in those with DME.2 In our study, 
we also noted that although the retinal and choroidal blood 
flow significantly decreased in the kallidinogenase untreated 
group, they remained unchanged in the treated group. This 
means that the treated group had relative increase in both 
retinal and choroidal blood flow compared to the untreated 
group. Therefore, we suggest that chorioretinal blood flow 
and its enhancement are more important than the changes in 
choroidal thickness. In this study, we confirmed that there 
was a statistical difference between the two groups after 
6 months of follow-up as regards to choroidal blood flow, and 
significant negative correlation between BCVA and retinal 
blood flow was noted in the treated group at 6 months. LSFG 
allows for noninvasive quantification of the microcircula-
tion in the optic disc, choroid, and retinal vessels separately 
in living eyes.16–18 LSFG method is therefore suitable for 
monitoring the time course of changes in tissue circulation 
at the same site in the same eye at various intervals, ranging 
from seconds to months.29,30 There are limitations to this 
































Figure 3 (A) Change in the mean blur rate (MBR) at the disc as the retinal blood flow. Although the retinal blood flow significantly decreased in the untreated group at 3 
and 6 months from baseline (*P,0.05), it remained unchanged during the whole follow-up period in the treated group. (B) Change in MBR at the macula as the choroidal 
blood flow. Although the choroidal blood flow significantly decreased in the untreated group at 6 months from baseline (*P,0.05), it remained unchanged during the whole 


























Figure 4 Spearman’s correlation between the mean blur rate (MBR) at the disc and 
the best-corrected visual acuity (BCVA). Significant negative correlation between 
BCVA and retinal blood flow was noted in the treated group at 6 months (P=0.01).
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Effects of oral kallidinogenase on diabetic macular edema
kallidinogenase is not used for ocular diseases in the West. 
Further studies targeting more patients or combinations with 
anti-VEGF therapy are considered to be necessary.
Conclusion
We conclude that kallidinogenase is able to improve chori-
oretinal blood flow levels in DME patients, and this improve-
ment was associated with the improvement in BCVA. 
In addition, the measurement of retinal blood flow by LSFG 
is potentially useful as a prognostic factor for BCVA and oral 
kallidinogenase medication is useful as an adjuvant therapy 
to enhance the therapeutic effect of STTA in DME patients. 
This study may be a novel contribution in the investigation 
of new possible therapies for the treatment of DME.
Disclosure
The authors report no conflicts of interest in this work.
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